Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Kymera Therapeutics's market cap was $11.16B on Nov 11, 2026, against $4.87B a year earlier. Over the last 5 years it ranged from $646.40M to $11.16B, with a median of $2.18B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $11.16B | +100.0% |
| 2025 | Dec 31, 2025 | $5.58B | +114.3% |
| 2024 | Dec 31, 2024 | $2.60B | +84.5% |
| 2023 | Dec 29, 2023 | $1.41B | +3.3% |
| 2022 | Dec 30, 2022 | $1.37B | -58.0% |
| 2021 | Dec 31, 2021 | $3.25B | +18.1% |
| 2020 | Dec 31, 2020 | $2.76B | – |
See a number that looks wrong?